INMB — Inmune Bio Income Statement
0.000.00%
Last trade - 00:00
- $152.36m
- $126.44m
- $0.16m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.011 | 0.181 | 0.374 | 0.155 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.76 | 12.2 | 29.3 | 26.3 | 29.9 |
Operating Profit | -7.76 | -12.2 | -29.2 | -26 | -29.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.68 | -12.1 | -30.3 | -27.3 | -30 |
Net Income After Taxes | -7.68 | -12.1 | -30.3 | -27.3 | -30 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.68 | -12.1 | -30.3 | -27.3 | -30 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.68 | -12.1 | -30.3 | -27.3 | -30 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.747 | -1.01 | -1.88 | -1.52 | -1.67 |